Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Down 53.1% in February

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the target of a large decrease in short interest in February. As of February 28th, there was short interest totalling 12,800 shares, a decrease of 53.1% from the February 13th total of 27,300 shares. Approximately 2.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 41,400 shares, the short-interest ratio is presently 0.3 days.

Titan Pharmaceuticals Trading Up 2.8 %

Shares of Titan Pharmaceuticals stock traded up $0.10 during trading on Friday, reaching $3.69. 25,783 shares of the stock traded hands, compared to its average volume of 136,214. The business has a fifty day simple moving average of $3.58 and a two-hundred day simple moving average of $4.18. Titan Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $14.80.

Titan Pharmaceuticals (NASDAQ:TTNP) last announced its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Titan Pharmaceuticals in a research report on Sunday, March 9th. They set a “sell” rating for the company.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.